CA2621517A1

CA2621517A1 - Production d'analogues de ligand fkbp polyketidiques

Production d'analogues de ligand fkbp polyketidiques Download PDF

Info

Publication number: CA2621517A1
Authority: CA; Canada
Prior art keywords: hydroxy; trans; desmethyl; cis; deoxo
Prior art date: 2002-07-16
Legal status : Granted

Application number

CA002621517A

Other languages

English (en)

Other versions

CA2621517C (fr

Inventor

Matthew Alan Gregory

Sabine Gaisser

Hrvoje Petkovic

Steven Moss

Current Assignee

Buck Institute for Research on Aging

Original Assignee

Individual

Priority date

2002-07-16

Filing date

2003-07-16

Publication date

2004-01-22

2002-07-16 Priority claimed from GB0216509A external-priority patent/GB0216509D0/en

2002-10-25 Priority claimed from GB0224922A external-priority patent/GB0224922D0/en

2003-07-16 Application filed by Individual filed Critical Individual

2003-07-16 Priority claimed from CA2492153A external-priority patent/CA2492153C/fr

2004-01-22 Publication of CA2621517A1 publication Critical patent/CA2621517A1/fr

2014-03-25 Application granted granted Critical

2014-03-25 Publication of CA2621517C publication Critical patent/CA2621517C/fr

2023-07-16 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000004519 manufacturing process Methods 0.000 title claims abstract description 88
229930001119 polyketide Natural products 0.000 title claims abstract description 55
239000003446 ligand Substances 0.000 title claims abstract description 41
125000000830 polyketide group Chemical group 0.000 title abstract description 14
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 354
229960002930 sirolimus Drugs 0.000 claims abstract description 306
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract description 286
108090000623 proteins and genes Proteins 0.000 claims abstract description 242
238000000034 method Methods 0.000 claims abstract description 209
150000003881 polyketide derivatives Chemical class 0.000 claims abstract description 42
230000008569 process Effects 0.000 claims abstract description 12
241000187391 Streptomyces hygroscopicus Species 0.000 claims description 172
101150042851 rapK gene Proteins 0.000 claims description 101
239000013612 plasmid Substances 0.000 claims description 96
239000007858 starting material Substances 0.000 claims description 93
101100467557 Streptomyces rapamycinicus (strain ATCC 29253 / DSM 41530 / NRRL 5491 / AYB-994) rapL gene Proteins 0.000 claims description 67
230000037430 deletion Effects 0.000 claims description 65
239000002253 acid Substances 0.000 claims description 64
238000012217 deletion Methods 0.000 claims description 63
239000002243 precursor Substances 0.000 claims description 49
241000905500 Streptomyces hygroscopicus subsp. ascomyceticus Species 0.000 claims description 42
101100467554 Bacillus subtilis (strain 168) rapJ gene Proteins 0.000 claims description 40
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 39
230000001851 biosynthetic effect Effects 0.000 claims description 36
241000187180 Streptomyces sp. Species 0.000 claims description 26
VZFUCHSFHOYXIS-UHFFFAOYSA-N Cycloheptanecarboxylic acid Chemical compound OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 claims description 24
241000588724 Escherichia coli Species 0.000 claims description 23
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 19
150000001413 amino acids Chemical class 0.000 claims description 19
230000001268 conjugating effect Effects 0.000 claims description 16
241001647839 Streptomyces tsukubensis Species 0.000 claims description 14
238000012258 culturing Methods 0.000 claims description 13
241000969734 Streptomyces hygroscopicus subsp. hygroscopicus Species 0.000 claims description 12
150000002148 esters Chemical class 0.000 claims description 12
241000187712 Actinoplanes sp. Species 0.000 claims description 10
229920001817 Agar Polymers 0.000 claims description 10
239000008272 agar Substances 0.000 claims description 10
230000021615 conjugation Effects 0.000 claims description 10
230000001419 dependent effect Effects 0.000 claims description 10
229910000019 calcium carbonate Inorganic materials 0.000 claims description 9
BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 9
241000187708 Micromonospora Species 0.000 claims description 8
240000008042 Zea mays Species 0.000 claims description 7
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 7
235000002017 Zea mays subsp mays Nutrition 0.000 claims description 7
235000005822 corn Nutrition 0.000 claims description 7
VUSWCWPCANWBFG-UHFFFAOYSA-N cyclohex-3-ene-1-carboxylic acid Chemical compound OC(=O)C1CCC=CC1 VUSWCWPCANWBFG-UHFFFAOYSA-N 0.000 claims description 7
FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 claims description 7
239000005569 Iron sulphate Substances 0.000 claims description 6
229920002472 Starch Polymers 0.000 claims description 6
229940041514 candida albicans extract Drugs 0.000 claims description 6
PFURGBBHAOXLIO-OLQVQODUSA-N cis-cyclohexane-1,2-diol Chemical compound O[C@H]1CCCC[C@H]1O PFURGBBHAOXLIO-OLQVQODUSA-N 0.000 claims description 6
LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 claims description 6
239000000843 powder Substances 0.000 claims description 6
239000012138 yeast extract Substances 0.000 claims description 6
OWLXUYGCLDGHJJ-UHFFFAOYSA-N 4-oxocyclohexanecarboxylic acid Chemical compound OC(=O)C1CCC(=O)CC1 OWLXUYGCLDGHJJ-UHFFFAOYSA-N 0.000 claims description 5
HJZLEGIHUQOJBA-UHFFFAOYSA-N cyclohexane propionic acid Chemical compound OC(=O)CCC1CCCCC1 HJZLEGIHUQOJBA-UHFFFAOYSA-N 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
BTYQWISIPUWRJR-UHFFFAOYSA-N tert-butyl 3-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate Chemical compound COC(=O)CC1CCCN(C(=O)OC(C)(C)C)C1 BTYQWISIPUWRJR-UHFFFAOYSA-N 0.000 claims description 5
PFURGBBHAOXLIO-PHDIDXHHSA-N trans-cyclohexane-1,2-diol Chemical compound O[C@@H]1CCCC[C@H]1O PFURGBBHAOXLIO-PHDIDXHHSA-N 0.000 claims description 5
230000001131 transforming effect Effects 0.000 claims description 5
101150100588 SAM gene Proteins 0.000 claims description 4
TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 claims description 4
FNFJZXAWCAEGNI-UHFFFAOYSA-N cycloheptene-1-carboxylic acid Chemical compound OC(=O)C1=CCCCCC1 FNFJZXAWCAEGNI-UHFFFAOYSA-N 0.000 claims description 4
JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 claims description 4
239000008107 starch Substances 0.000 claims description 4
235000019698 starch Nutrition 0.000 claims description 4
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 3
101710116650 FAD-dependent monooxygenase Proteins 0.000 claims description 3
108010074122 Ferredoxins Proteins 0.000 claims description 3
101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 claims description 3
101710128228 O-methyltransferase Proteins 0.000 claims description 3
239000013604 expression vector Substances 0.000 claims description 3
230000004580 weight loss Effects 0.000 claims description 3
REHQLKUNRPCYEW-UHFFFAOYSA-N 1-methylcyclohexane-1-carboxylic acid Chemical compound OC(=O)C1(C)CCCCC1 REHQLKUNRPCYEW-UHFFFAOYSA-N 0.000 claims description 2
JESWDXIHOJGWBP-UHFFFAOYSA-N bicyclo[2.2.1]heptane-3-carboxylic acid Chemical compound C1CC2C(C(=O)O)CC1C2 JESWDXIHOJGWBP-UHFFFAOYSA-N 0.000 claims description 2
101100467553 Bacillus subtilis (strain 168) rapI gene Proteins 0.000 claims 2
POROIMOHDIEBBO-UHFFFAOYSA-N 2-oxocyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1=O POROIMOHDIEBBO-UHFFFAOYSA-N 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 102
238000002955 isolation Methods 0.000 abstract description 53
239000013598 vector Substances 0.000 abstract description 40
230000009466 transformation Effects 0.000 abstract description 16
102000018679 Tacrolimus Binding Proteins Human genes 0.000 abstract description 15
229930014626 natural product Natural products 0.000 abstract description 13
108010027179 Tacrolimus Binding Proteins Proteins 0.000 abstract description 8
102000039446 nucleic acids Human genes 0.000 abstract description 7
108020004707 nucleic acids Proteins 0.000 abstract description 7
150000007523 nucleic acids Chemical class 0.000 abstract description 7
238000002360 preparation method Methods 0.000 abstract description 3
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 147
ZDQSOHOQTUFQEM-NURRSENYSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-NURRSENYSA-N 0.000 description 143
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 142
ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 131
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 109
125000000217 alkyl group Chemical group 0.000 description 73
239000000047 product Substances 0.000 description 69
239000000463 material Substances 0.000 description 60
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 53
239000012634 fragment Substances 0.000 description 52
239000002609 medium Substances 0.000 description 46
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 44
229910052799 carbon Inorganic materials 0.000 description 44
210000004027 cell Anatomy 0.000 description 44
101100523604 Mus musculus Rassf5 gene Proteins 0.000 description 43
230000015572 biosynthetic process Effects 0.000 description 43
125000000468 ketone group Chemical group 0.000 description 43
238000004458 analytical method Methods 0.000 description 42
229930194542 Keto Natural products 0.000 description 40
150000002500 ions Chemical class 0.000 description 40
230000004048 modification Effects 0.000 description 38
238000012986 modification Methods 0.000 description 38
108010030975 Polyketide Synthases Proteins 0.000 description 37
238000000855 fermentation Methods 0.000 description 37
230000004151 fermentation Effects 0.000 description 37
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
108091008053 gene clusters Proteins 0.000 description 33
229910052739 hydrogen Inorganic materials 0.000 description 32
HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 32
238000010348 incorporation Methods 0.000 description 31
-1 pipecolic acid lactone Chemical class 0.000 description 31
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 30
HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 29
101100066722 Streptomyces hygroscopicus fkbO gene Proteins 0.000 description 28
NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 28
125000001475 halogen functional group Chemical group 0.000 description 28
230000006870 function Effects 0.000 description 27
108020004414 DNA Proteins 0.000 description 26
108091028043 Nucleic acid sequence Proteins 0.000 description 25
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
238000011282 treatment Methods 0.000 description 24
230000000694 effects Effects 0.000 description 23
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 22
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 22
235000010633 broth Nutrition 0.000 description 22
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 21
229910001868 water Inorganic materials 0.000 description 21
229930188060 antascomicin Natural products 0.000 description 19
238000010367 cloning Methods 0.000 description 19
101100509371 Arabidopsis thaliana CHR11 gene Proteins 0.000 description 18
102000004190 Enzymes Human genes 0.000 description 18
108090000790 Enzymes Proteins 0.000 description 18
238000012300 Sequence Analysis Methods 0.000 description 18
UNSKIISCJFJWTL-WIDVRGBZSA-N meridamycin Chemical compound C1C(O)C(C)C(O)CC(O)CC(O)\C(C)=C\C(C)CC(C)C(O)C(/CC)=C/CC(C(\C)=C\C(C)C(C)O)OC(=O)C2CCCN2C(=O)C(=O)C2(O)C(C)CCC1O2 UNSKIISCJFJWTL-WIDVRGBZSA-N 0.000 description 18
DGKUOWHAUIWQTM-UHFFFAOYSA-N meridamycin Natural products C1C(O)C(C)C(O)CC(O)CC(O)C(C)=CC(C)CC(C)C(O)C(CC)=CCC(C(C)=CC(C)C(C)O)OC(=O)C2CCCCN2C(=O)C(=O)C2(O)C(C)CCC1O2 DGKUOWHAUIWQTM-UHFFFAOYSA-N 0.000 description 18
230000036961 partial effect Effects 0.000 description 18
RUAWAUYKGXTUTF-MMZIUCNJSA-N prolylrapamycin Chemical compound C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)/C(C)=C/C=C/C=C/C(C)CC(C)C(=O)C(OC)C(O)/C(C)=C/C(C)C(=O)C1 RUAWAUYKGXTUTF-MMZIUCNJSA-N 0.000 description 18
229940024606 amino acid Drugs 0.000 description 17
235000001014 amino acid Nutrition 0.000 description 17
ZJFDZKAGRTZFDZ-UHFFFAOYSA-N 4,5-dihydroxycyclohexene-1-carboxylic acid Chemical compound OC1CC=C(C(O)=O)CC1O ZJFDZKAGRTZFDZ-UHFFFAOYSA-N 0.000 description 16
125000003308 polyketide hybrid group Chemical group 0.000 description 16
238000010561 standard procedure Methods 0.000 description 16
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
241000828254 Streptomyces lividans TK24 Species 0.000 description 15
230000000295 complement effect Effects 0.000 description 15
239000003018 immunosuppressive agent Substances 0.000 description 15
239000000203 mixture Substances 0.000 description 15
229960005322 streptomycin Drugs 0.000 description 15
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 14
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 14
238000012937 correction Methods 0.000 description 14
239000000284 extract Substances 0.000 description 14
230000002829 reductive effect Effects 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
ASIMJELWCFGQLM-UHFFFAOYSA-N 9-deoxo-16-O-desmethyl-27-desmethoxy-39-O-desmethylrapamycin Natural products C1C(=O)C(C)C=C(C)C(O)CC(=O)C(C)CC(C)C=CC=CC=C(C)C(O)CC(O2)CCC(C)C2(O)CC(=O)N2CCCCC2C(=O)OC1C(C)CC1CCC(O)C(O)C1 ASIMJELWCFGQLM-UHFFFAOYSA-N 0.000 description 13
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 description 13
229950006334 apramycin Drugs 0.000 description 13
229960003444 immunosuppressant agent Drugs 0.000 description 13
230000010354 integration Effects 0.000 description 13
HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 13
239000002904 solvent Substances 0.000 description 13
102000000521 Immunophilins Human genes 0.000 description 12
108010016648 Immunophilins Proteins 0.000 description 12
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 12
238000013459 approach Methods 0.000 description 12
150000001735 carboxylic acids Chemical class 0.000 description 12
235000019439 ethyl acetate Nutrition 0.000 description 12
238000013467 fragmentation Methods 0.000 description 12
238000006062 fragmentation reaction Methods 0.000 description 12
238000004128 high performance liquid chromatography Methods 0.000 description 12
230000001506 immunosuppresive effect Effects 0.000 description 12
238000003786 synthesis reaction Methods 0.000 description 12
206010061764 Chromosomal deletion Diseases 0.000 description 11
102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 11
240000004808 Saccharomyces cerevisiae Species 0.000 description 11
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
238000010276 construction Methods 0.000 description 11
238000001514 detection method Methods 0.000 description 11
230000014509 gene expression Effects 0.000 description 11
229960002429 proline Drugs 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 10
150000007513 acids Chemical class 0.000 description 10
230000008878 coupling Effects 0.000 description 10
238000010168 coupling process Methods 0.000 description 10
238000005859 coupling reaction Methods 0.000 description 10
229940093499 ethyl acetate Drugs 0.000 description 10
230000012010 growth Effects 0.000 description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
230000001861 immunosuppressant effect Effects 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
150000002576 ketones Chemical class 0.000 description 10
229930001118 polyketide hybrid Natural products 0.000 description 10
238000002953 preparative HPLC Methods 0.000 description 10
238000012360 testing method Methods 0.000 description 10
UHOYMAQUMOLYAF-UHFFFAOYSA-N 16-O-desmethyl-27-desmethoxyrapamycin Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(O)C(C)=CC=CC=CC(C)CC(C)C(=O)CC(O)C(C)=CC(C)C(=O)C1 UHOYMAQUMOLYAF-UHFFFAOYSA-N 0.000 description 9
206010028980 Neoplasm Diseases 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000003242 anti bacterial agent Substances 0.000 description 9
230000000843 anti-fungal effect Effects 0.000 description 9
229940088710 antibiotic agent Drugs 0.000 description 9
PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 9
239000003814 drug Substances 0.000 description 9
238000000605 extraction Methods 0.000 description 9
238000004949 mass spectrometry Methods 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
230000035755 proliferation Effects 0.000 description 9
235000018102 proteins Nutrition 0.000 description 9
230000019491 signal transduction Effects 0.000 description 9
QJZFOXSQKWYZLH-UHFFFAOYSA-N 9-deoxo-16-O-desmethyl-27-desmethoxy-rapamycin Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)CC(O)(O2)C(C)CCC2CC(O)C(C)=CC=CC=CC(C)CC(C)C(=O)CC(O)C(C)=CC(C)C(=O)C1 QJZFOXSQKWYZLH-UHFFFAOYSA-N 0.000 description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
230000036983 biotransformation Effects 0.000 description 8
235000010216 calcium carbonate Nutrition 0.000 description 8
239000000306 component Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 8
230000003993 interaction Effects 0.000 description 8
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
230000014759 maintenance of location Effects 0.000 description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
230000011987 methylation Effects 0.000 description 8
238000007069 methylation reaction Methods 0.000 description 8
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 8
239000000126 substance Substances 0.000 description 8
230000014616 translation Effects 0.000 description 8
238000002054 transplantation Methods 0.000 description 8
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 7
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 7
108091011114 FK506 binding proteins Proteins 0.000 description 7
206010016654 Fibrosis Diseases 0.000 description 7
206010062016 Immunosuppression Diseases 0.000 description 7
238000005481 NMR spectroscopy Methods 0.000 description 7
238000003556 assay Methods 0.000 description 7
HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 7
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 7
230000004761 fibrosis Effects 0.000 description 7
239000008103 glucose Substances 0.000 description 7
230000002779 inactivation Effects 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
239000003120 macrolide antibiotic agent Substances 0.000 description 7
108010000785 non-ribosomal peptide synthase Proteins 0.000 description 7
235000013930 proline Nutrition 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
150000003573 thiols Chemical class 0.000 description 7
238000000825 ultraviolet detection Methods 0.000 description 7
DAJSJYOJOCPXDB-UHFFFAOYSA-N 9-deoxo-27-desmethoxyrapamycin Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)CC(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)CC(O)C(C)=CC(C)C(=O)C1 DAJSJYOJOCPXDB-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
102100034343 Integrase Human genes 0.000 description 6
108010061833 Integrases Proteins 0.000 description 6
235000019766 L-Lysine Nutrition 0.000 description 6
239000004472 Lysine Substances 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
201000004681 Psoriasis Diseases 0.000 description 6
241000187398 Streptomyces lividans Species 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 6
239000013078 crystal Substances 0.000 description 6
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
238000012546 transfer Methods 0.000 description 6
102000002260 Alkaline Phosphatase Human genes 0.000 description 5
108020004774 Alkaline Phosphatase Proteins 0.000 description 5
241001598984 Bromius obscurus Species 0.000 description 5
101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 description 5
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
229930105110 Cyclosporin A Natural products 0.000 description 5
108010036949 Cyclosporine Proteins 0.000 description 5
102100025894 Glomulin Human genes 0.000 description 5
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 5
241000187559 Saccharopolyspora erythraea Species 0.000 description 5
241001468227 Streptomyces avermitilis Species 0.000 description 5
241000531819 Streptomyces venezuelae Species 0.000 description 5
241000534944 Thia Species 0.000 description 5
230000009471 action Effects 0.000 description 5
230000004075 alteration Effects 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
229940121375 antifungal agent Drugs 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
229940125904 compound 1 Drugs 0.000 description 5
201000010099 disease Diseases 0.000 description 5
239000012636 effector Substances 0.000 description 5
235000013312 flour Nutrition 0.000 description 5
238000011534 incubation Methods 0.000 description 5
230000035772 mutation Effects 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
230000003647 oxidation Effects 0.000 description 5
238000007254 oxidation reaction Methods 0.000 description 5
150000002924 oxiranes Chemical class 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
238000010188 recombinant method Methods 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
238000012552 review Methods 0.000 description 5
206010039073 rheumatoid arthritis Diseases 0.000 description 5
239000000523 sample Substances 0.000 description 5
JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 5
JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 5
239000000377 silicon dioxide Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
230000003393 splenic effect Effects 0.000 description 5
241001446247 uncultured actinomycete Species 0.000 description 5
241001468213 Amycolatopsis mediterranei Species 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
241000222122 Candida albicans Species 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
101710088083 Glomulin Proteins 0.000 description 4
244000068988 Glycine max Species 0.000 description 4
235000010469 Glycine max Nutrition 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
239000007836 KH2PO4 Substances 0.000 description 4
229930182821 L-proline Natural products 0.000 description 4
241001529936 Murinae Species 0.000 description 4
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
101100280043 Saccharopolyspora erythraea eryBV gene Proteins 0.000 description 4
241000187747 Streptomyces Species 0.000 description 4
241000187434 Streptomyces cinnamonensis Species 0.000 description 4
241000187432 Streptomyces coelicolor Species 0.000 description 4
241000187438 Streptomyces fradiae Species 0.000 description 4
241001312733 Streptomyces griseofuscus Species 0.000 description 4
241001134665 Streptomyces longisporoflavus Species 0.000 description 4
241000187419 Streptomyces rimosus Species 0.000 description 4
229910052921 ammonium sulfate Inorganic materials 0.000 description 4
230000003115 biocidal effect Effects 0.000 description 4
238000010170 biological method Methods 0.000 description 4
150000007942 carboxylates Chemical class 0.000 description 4
238000007385 chemical modification Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
101150065241 fkbO gene Proteins 0.000 description 4
238000012224 gene deletion Methods 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
230000003463 hyperproliferative effect Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
229940041033 macrolides Drugs 0.000 description 4
230000002503 metabolic effect Effects 0.000 description 4
244000005700 microbiome Species 0.000 description 4
229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
235000019796 monopotassium phosphate Nutrition 0.000 description 4
IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 4
230000003018 neuroregenerative effect Effects 0.000 description 4
230000008520 organization Effects 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 4
230000002265 prevention Effects 0.000 description 4
DAIKHDNSXMZDCU-OUDXUNEISA-N pristinamycin-IIA Natural products CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c3coc(CC(=O)C[C@H](O)C=C(C)C=CCNC(=O)C=C[C@@H]1C)n3 DAIKHDNSXMZDCU-OUDXUNEISA-N 0.000 description 4
238000001243 protein synthesis Methods 0.000 description 4
230000006798 recombination Effects 0.000 description 4
238000005215 recombination Methods 0.000 description 4
101150098466 rpsL gene Proteins 0.000 description 4
102220095236 rs876658436 Human genes 0.000 description 4
230000011664 signaling Effects 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000004885 tandem mass spectrometry Methods 0.000 description 4
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
OSJRHIPIBCOBCT-UHFFFAOYSA-N 1-methoxycyclohexane-1-carboxylic acid Chemical compound COC1(C(O)=O)CCCCC1 OSJRHIPIBCOBCT-UHFFFAOYSA-N 0.000 description 3
HCTKMJTWWIYORY-UHFFFAOYSA-N 16-O-desmethyl-39-desmethoxyrapamycin Natural products O1C(=O)C2CCCCN2C(=O)C(=O)C(C(CC2)C)(O)OC2CC(O)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)CC1C(C)CC1CCC(O)CC1 HCTKMJTWWIYORY-UHFFFAOYSA-N 0.000 description 3
CVKMFSAVYPAZTQ-UHFFFAOYSA-N 2-methylhexanoic acid Chemical compound CCCCC(C)C(O)=O CVKMFSAVYPAZTQ-UHFFFAOYSA-N 0.000 description 3
CIFSKZDQGRCLBN-UHFFFAOYSA-N 3-methylcyclohexane-1-carboxylic acid Chemical compound CC1CCCC(C(O)=O)C1 CIFSKZDQGRCLBN-UHFFFAOYSA-N 0.000 description 3
238000011740 C57BL/6 mouse Methods 0.000 description 3
101000979117 Curvularia clavata Nonribosomal peptide synthetase Proteins 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
229920001353 Dextrin Polymers 0.000 description 3
239000004375 Dextrin Substances 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
101001060744 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP1A Proteins 0.000 description 3
101000827313 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP3 Proteins 0.000 description 3
101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
241001134671 Micromonospora griseorubida Species 0.000 description 3
108091007960 PI3Ks Proteins 0.000 description 3
102100026408 Peptidyl-prolyl cis-trans isomerase FKBP2 Human genes 0.000 description 3
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
108010019477 S-adenosyl-L-methionine-dependent N-methyltransferase Proteins 0.000 description 3
102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
108010085012 Steroid Receptors Proteins 0.000 description 3
102000007451 Steroid Receptors Human genes 0.000 description 3
101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 3
108010015791 Streptogramin A Proteins 0.000 description 3
241000187759 Streptomyces albus Species 0.000 description 3
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 3
230000007815 allergy Effects 0.000 description 3
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
235000011130 ammonium sulphate Nutrition 0.000 description 3
238000002827 antifungal susceptibility testing Methods 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
238000002815 broth microdilution Methods 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
230000008859 change Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229960001265 ciclosporin Drugs 0.000 description 3
PDXRQENMIVHKPI-UHFFFAOYSA-N cyclohexane-1,1-diol Chemical compound OC1(O)CCCCC1 PDXRQENMIVHKPI-UHFFFAOYSA-N 0.000 description 3
238000001212 derivatisation Methods 0.000 description 3
235000019425 dextrin Nutrition 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
239000013613 expression plasmid Substances 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
238000003919 heteronuclear multiple bond coherence Methods 0.000 description 3
238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 3
MNWFXJYAOYHMED-UHFFFAOYSA-N hexane carboxylic acid Natural products CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
230000000415 inactivating effect Effects 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
229910000359 iron(II) sulfate Inorganic materials 0.000 description 3
150000002596 lactones Chemical class 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 3
229910000357 manganese(II) sulfate Inorganic materials 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 3
229960000210 nalidixic acid Drugs 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
ZHFMVVUVCALAMY-UHFFFAOYSA-N pipecolate Natural products OC1CNC(C(O)=O)C(O)C1O ZHFMVVUVCALAMY-UHFFFAOYSA-N 0.000 description 3
JOOMGSFOCRDAHL-XKCHLWDXSA-N pristinamycin-IIB Natural products CC(C)[C@@H]1OC(=O)[C@H]2CCCN2C(=O)c3coc(CC(=O)C[C@@H](O)C=C(C)C=CCNC(=O)C=C[C@H]1C)n3 JOOMGSFOCRDAHL-XKCHLWDXSA-N 0.000 description 3
239000013587 production medium Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000007430 reference method Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
102220216906 rs1060505002 Human genes 0.000 description 3
102220228145 rs1064794513 Human genes 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
229960001967 tacrolimus Drugs 0.000 description 3
230000008685 targeting Effects 0.000 description 3
229960000235 temsirolimus Drugs 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000001551 total correlation spectroscopy Methods 0.000 description 3
239000011573 trace mineral Substances 0.000 description 3
235000013619 trace mineral Nutrition 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
238000013519 translation Methods 0.000 description 3
239000001974 tryptic soy broth Substances 0.000 description 3
GYJREHMTTLYKRJ-UHFFFAOYSA-N 3-(2-fluorophenyl)-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C=1C=CC=CC=1COC(=O)NC(C(=O)O)CC1=CC=CC=C1F GYJREHMTTLYKRJ-UHFFFAOYSA-N 0.000 description 2
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
JBZDHFKPEDWWJC-UHFFFAOYSA-N 3-hydroxycyclohexane-1-carboxylic acid Chemical compound OC1CCCC(C(O)=O)C1 JBZDHFKPEDWWJC-UHFFFAOYSA-N 0.000 description 2
QTDXSEZXAPHVBI-UHFFFAOYSA-N 4-methylcyclohexane-1-carboxylic acid Chemical compound CC1CCC(C(O)=O)CC1 QTDXSEZXAPHVBI-UHFFFAOYSA-N 0.000 description 2
YVMBAUWDIGJRNY-BESUKNQGSA-N 4o8o7q7iu4 Chemical compound C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YVMBAUWDIGJRNY-BESUKNQGSA-N 0.000 description 2
RKEYKDXXZCICFZ-UHFFFAOYSA-N 5-hydroxypipecolic acid Chemical compound OC1CCC(C(O)=O)NC1 RKEYKDXXZCICFZ-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
241000186361 Actinobacteria <class> Species 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
108010006654 Bleomycin Proteins 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
101150041968 CDC13 gene Proteins 0.000 description 2
102000005228 Cyclic AMP Response Element Modulator Human genes 0.000 description 2
108010056281 Cyclic AMP Response Element Modulator Proteins 0.000 description 2
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 description 2
101710104441 FK506-binding protein 1 Proteins 0.000 description 2
101710132880 FK506-binding protein 1A Proteins 0.000 description 2
101710132879 FK506-binding protein 1B Proteins 0.000 description 2
238000004252 FT/ICR mass spectrometry Methods 0.000 description 2
108700007698 Genetic Terminator Regions Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
241000187480 Mycobacterium smegmatis Species 0.000 description 2
241000187479 Mycobacterium tuberculosis Species 0.000 description 2
241001429274 Mycobacterium virus L5 Species 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
102100023846 Peptidyl-prolyl cis-trans isomerase FKBP3 Human genes 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
108010079780 Pristinamycin Proteins 0.000 description 2
RLNUPSVMIYRZSM-UHFFFAOYSA-N Pristinamycin Natural products CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC(=CC=2)N(C)C)CCN(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O RLNUPSVMIYRZSM-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
108091008611 Protein Kinase B Proteins 0.000 description 2
102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
101000708945 Serratia sp. (strain ATCC 39006) Transcriptional regulator SlyA Proteins 0.000 description 2
241001446311 Streptomyces coelicolor A3(2) Species 0.000 description 2
241001518258 Streptomyces pristinaespiralis Species 0.000 description 2
101100066721 Streptomyces tacrolimicus fkbM gene Proteins 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
VCVJSWDSNWXXJT-UHFFFAOYSA-N [4-(1-methylpyrazol-3-yl)phenyl]methanol Chemical compound CN1C=CC(C=2C=CC(CO)=CC=2)=N1 VCVJSWDSNWXXJT-UHFFFAOYSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
RMRFFCXPLWYOOY-UHFFFAOYSA-N allyl radical Chemical group [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
239000002518 antifoaming agent Substances 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
229960001561 bleomycin Drugs 0.000 description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
102220414581 c.33A>G Human genes 0.000 description 2
229940095731 candida albicans Drugs 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000013611 chromosomal DNA Substances 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
239000013068 control sample Substances 0.000 description 2
238000005100 correlation spectroscopy Methods 0.000 description 2
239000000287 crude extract Substances 0.000 description 2
230000002338 cryopreservative effect Effects 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
DMEGYFMYUHOHGS-UHFFFAOYSA-N cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical group OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
ZWAJLVLEBYIOTI-UHFFFAOYSA-N cyclohexene oxide Chemical compound C1CCCC2OC21 ZWAJLVLEBYIOTI-UHFFFAOYSA-N 0.000 description 2
FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohexene oxide Natural products O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
230000009088 enzymatic function Effects 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
229960005167 everolimus Drugs 0.000 description 2
231100000221 frame shift mutation induction Toxicity 0.000 description 2
230000037433 frameshift Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
230000033444 hydroxylation Effects 0.000 description 2
238000005805 hydroxylation reaction Methods 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000006317 isomerization reaction Methods 0.000 description 2
229960000318 kanamycin Drugs 0.000 description 2
229930027917 kanamycin Natural products 0.000 description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
229930182823 kanamycin A Natural products 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000011068 loading method Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012533 medium component Substances 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical group CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
230000014511 neuron projection development Effects 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
230000037361 pathway Effects 0.000 description 2
238000009522 phase III clinical trial Methods 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
229960005190 phenylalanine Drugs 0.000 description 2
235000008729 phenylalanine Nutrition 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
229960003961 pristinamycin Drugs 0.000 description 2
DAIKHDNSXMZDCU-FQTGFAPKSA-N pristinamycin IIA Chemical compound C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2 DAIKHDNSXMZDCU-FQTGFAPKSA-N 0.000 description 2
DAIKHDNSXMZDCU-UHFFFAOYSA-N pristinamycin component IIA Natural products C1C(=O)CC(O)C=C(C)C=CCNC(=O)C=CC(C)C(C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2 DAIKHDNSXMZDCU-UHFFFAOYSA-N 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000009696 proliferative response Effects 0.000 description 2
230000012846 protein folding Effects 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000007142 ring opening reaction Methods 0.000 description 2
102220090095 rs1042713 Human genes 0.000 description 2
102220264750 rs1305455942 Human genes 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
108010067247 tacrolimus binding protein 4 Proteins 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
150000005671 trienes Chemical group 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
229940100445 wheat starch Drugs 0.000 description 2
BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
KRHNXNZBLHHEIU-RFZPGFLSSA-N (2r,4r)-4-hydroxypiperidin-1-ium-2-carboxylate Chemical compound O[C@@H]1CCN[C@@H](C(O)=O)C1 KRHNXNZBLHHEIU-RFZPGFLSSA-N 0.000 description 1
KKJQZEWNZXRJFG-CRCLSJGQSA-N (2r,4s)-4-methylpyrrolidin-1-ium-2-carboxylate Chemical compound C[C@@H]1CN[C@@H](C(O)=O)C1 KKJQZEWNZXRJFG-CRCLSJGQSA-N 0.000 description 1
FGMPLJWBKKVCDB-BYPYZUCNSA-N (2s)-1-hydroxypyrrolidine-2-carboxylic acid Chemical compound ON1CCC[C@H]1C(O)=O FGMPLJWBKKVCDB-BYPYZUCNSA-N 0.000 description 1
QQOQGDXPWMKBGS-DFWYDOINSA-N (2s)-5-amino-3,4-dihydro-2h-pyrrole-2-carboxylic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H]1CCC(=N)N1 QQOQGDXPWMKBGS-DFWYDOINSA-N 0.000 description 1
CNPSFBUUYIVHAP-WHFBIAKZSA-N (2s,3s)-3-methylpyrrolidin-1-ium-2-carboxylate Chemical compound C[C@H]1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-WHFBIAKZSA-N 0.000 description 1
SHINASQYHDCLEU-DMTCNVIQSA-N (2s,4r)-4-aminopyrrolidine-2-carboxylic acid Chemical compound N[C@H]1CN[C@H](C(O)=O)C1 SHINASQYHDCLEU-DMTCNVIQSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
ACHWOAWMCHWXIO-UHFFFAOYSA-N 1-chlorocyclohexane-1-carboxylic acid Chemical compound OC(=O)C1(Cl)CCCCC1 ACHWOAWMCHWXIO-UHFFFAOYSA-N 0.000 description 1
IALUZFHYHBLCEE-UHFFFAOYSA-N 1-ethyl-2-oxocyclohexane-1-carboxylic acid Chemical compound CCC1(C(O)=O)CCCCC1=O IALUZFHYHBLCEE-UHFFFAOYSA-N 0.000 description 1
UBQBKOBGHRTZRG-UPAXIQFWSA-N 104987-09-9 Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 UBQBKOBGHRTZRG-UPAXIQFWSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
JNKCXIWJIVUIMN-RXMQYKEDSA-N 2-hydroxy-L-proline Chemical compound OC(=O)[C@]1(O)CCCN1 JNKCXIWJIVUIMN-RXMQYKEDSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
ZNGINKJHQQQORD-UHFFFAOYSA-N 2-trimethylsilylethanol Chemical compound C[Si](C)(C)CCO ZNGINKJHQQQORD-UHFFFAOYSA-N 0.000 description 1
FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical class S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
ZAPWVTMLZNPUPQ-UHFFFAOYSA-N 4,4-dihydroxycyclohexane-1-carboxylic acid Chemical compound OC(=O)C1CCC(O)(O)CC1 ZAPWVTMLZNPUPQ-UHFFFAOYSA-N 0.000 description 1
USEYFCOAPFGKLX-JTQLQIEISA-N 4-Dimethylamino-L-phenylalanine Chemical compound CN(C)C1=CC=C(C[C@H](N)C(O)=O)C=C1 USEYFCOAPFGKLX-JTQLQIEISA-N 0.000 description 1
HCFRWBBJISAZNK-UHFFFAOYSA-N 4-Hydroxycyclohexylcarboxylic acid Chemical compound OC1CCC(C(O)=O)CC1 HCFRWBBJISAZNK-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
MSTVTNQRWDYSNC-UHFFFAOYSA-N 4-chloro-3-hydroxycyclohexane-1-carboxylic acid Chemical compound OC1CC(C(O)=O)CCC1Cl MSTVTNQRWDYSNC-UHFFFAOYSA-N 0.000 description 1
OKSDJGWHKXFVME-UHFFFAOYSA-N 4-ethylcyclohexan-1-one Chemical compound CCC1CCC(=O)CC1 OKSDJGWHKXFVME-UHFFFAOYSA-N 0.000 description 1
RDHDHMIARRLJNV-UHFFFAOYSA-N 4-ethylmorpholine;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.CCN1CCOCC1 RDHDHMIARRLJNV-UHFFFAOYSA-N 0.000 description 1
102100023912 40S ribosomal protein S12 Human genes 0.000 description 1
DIEORUOOFDNDCG-UHFFFAOYSA-N 41-desmethoxyrapamycin 31-OTMS Natural products C1C(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C(C)C(OC)CC(O2)CCC(C)C2(O)C(=O)C(=O)N2CCCCC2C(=O)OC1C(C)CC1CCC(O)CC1 DIEORUOOFDNDCG-UHFFFAOYSA-N 0.000 description 1
ZLAQAINRRWCPLX-UHFFFAOYSA-N 5-chloropiperidine-2-carboxylic acid Chemical compound OC(=O)C1CCC(Cl)CN1 ZLAQAINRRWCPLX-UHFFFAOYSA-N 0.000 description 1
CNPPQIVHKLYCGG-UHFFFAOYSA-N 5-hydroxycyclohex-3-ene-1-carboxylic acid Chemical compound OC1CC(C(O)=O)CC=C1 CNPPQIVHKLYCGG-UHFFFAOYSA-N 0.000 description 1
108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
BZIJTRUWBLMPKL-UHFFFAOYSA-N 9-deoxo-27-desmethoxy-39-O-desmethylrapamycin Natural products C1C(=O)C(C)C=C(C)C(O)CC(=O)C(C)CC(C)C=CC=CC=C(C)C(OC)CC(O2)CCC(C)C2(O)CC(=O)N2CCCCC2C(=O)OC1C(C)CC1CCC(O)C(O)C1 BZIJTRUWBLMPKL-UHFFFAOYSA-N 0.000 description 1
239000005660 Abamectin Substances 0.000 description 1
101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
241000187844 Actinoplanes Species 0.000 description 1
VTIKDEXOEJDMJP-UHFFFAOYSA-N Actinorhodine Natural products CC1OC(CC(=O)O)CC2=C1C(=O)c3c(O)c(cc(O)c3C2=O)c4cc(O)c5C(=O)C6=C(C(C)OC(CC(=O)O)C6)C(=O)c5c4O VTIKDEXOEJDMJP-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
101100165658 Alternaria brassicicola bsc5 gene Proteins 0.000 description 1
102000034263 Amino acid transporters Human genes 0.000 description 1
108050005273 Amino acid transporters Proteins 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
101100322812 Arabidopsis thaliana AHL21 gene Proteins 0.000 description 1
101100322813 Arabidopsis thaliana AHL22 gene Proteins 0.000 description 1
101100277337 Arabidopsis thaliana DDM1 gene Proteins 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
101100032924 Bacillus subtilis (strain 168) radA gene Proteins 0.000 description 1
FQQYOXPFBMYCPO-AURGRMCHSA-N C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](O)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](O)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 FQQYOXPFBMYCPO-AURGRMCHSA-N 0.000 description 1
238000011749 CBA mouse Methods 0.000 description 1
108091007914 CDKs Proteins 0.000 description 1
101100447653 Caenorhabditis elegans phg-1 gene Proteins 0.000 description 1
101100510323 Caenorhabditis elegans pkc-1 gene Proteins 0.000 description 1
244000197813 Camelina sativa Species 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
101710134389 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2 Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
NMEZJSDUZQOPFE-UHFFFAOYSA-N Cyclohex-1-enecarboxylic acid Chemical compound OC(=O)C1=CCCCC1 NMEZJSDUZQOPFE-UHFFFAOYSA-N 0.000 description 1
102000001493 Cyclophilins Human genes 0.000 description 1
108010068682 Cyclophilins Proteins 0.000 description 1
208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
101100492392 Didymella fabae pksAC gene Proteins 0.000 description 1
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
102000016680 Dioxygenases Human genes 0.000 description 1
108010028143 Dioxygenases Proteins 0.000 description 1
DYUAQFZABAEMQI-UHFFFAOYSA-N Elaiophylin Natural products CCC1C(C)OC(O)(CC1OC2CC(O)C(O)C(C)O2)C(C)C(O)C(C)C(OC(=O)C=CC=CC(C)C(OC(=O)C=CC=C)C(C)C(O)C(C)C3(O)CC(OC4CC(O)C(O)C(C)O4)C(CC)C(C)O3)C(C)C DYUAQFZABAEMQI-UHFFFAOYSA-N 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 description 1
108010069271 FKBP-13 Proteins 0.000 description 1
201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108700023372 Glycosyltransferases Proteins 0.000 description 1
241000055890 Gorceixia Species 0.000 description 1
241000629264 Halicreas minimum Species 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
101000857303 Homo sapiens Glomulin Proteins 0.000 description 1
101000891031 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP10 Proteins 0.000 description 1
101001031398 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP9 Proteins 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
101710154620 NADH:riboflavin 5'-phosphate oxidoreductase Proteins 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
241000244489 Navia Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
KRHNXNZBLHHEIU-UHFFFAOYSA-N Pegaline Natural products OC1CCNC(C(O)=O)C1 KRHNXNZBLHHEIU-UHFFFAOYSA-N 0.000 description 1
108010068204 Peptide Elongation Factors Proteins 0.000 description 1
102000002508 Peptide Elongation Factors Human genes 0.000 description 1
108700018928 Peptide Synthases Proteins 0.000 description 1
102000056222 Peptide Synthases Human genes 0.000 description 1
102100040349 Peptidyl-prolyl cis-trans isomerase FKBP10 Human genes 0.000 description 1
102100027914 Peptidyl-prolyl cis-trans isomerase FKBP1B Human genes 0.000 description 1
102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 description 1
102100038809 Peptidyl-prolyl cis-trans isomerase FKBP9 Human genes 0.000 description 1
101100226893 Phomopsis amygdali PaP450-2 gene Proteins 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108091007187 Reductases Proteins 0.000 description 1
108700005075 Regulator Genes Proteins 0.000 description 1
206010063897 Renal ischaemia Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
102000003861 Ribosomal protein S6 Human genes 0.000 description 1
108090000221 Ribosomal protein S6 Proteins 0.000 description 1
230000018199 S phase Effects 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
108010052160 Site-specific recombinase Proteins 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
241000958215 Streptomyces filamentosus Species 0.000 description 1
241000702139 Streptomyces phage VWB Species 0.000 description 1
241001147844 Streptomyces verticillus Species 0.000 description 1
241001655322 Streptomycetales Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
102100036236 Synaptonemal complex protein 2 Human genes 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
241000222126 [Candida] glabrata Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
VTIKDEXOEJDMJP-WYUUTHIRSA-N actinorhodin Chemical compound C([C@@H](CC(O)=O)O[C@@H]1C)C(C(C2=C(O)C=3)=O)=C1C(=O)C2=C(O)C=3C(C(=C1C2=O)O)=CC(O)=C1C(=O)C1=C2[C@@H](C)O[C@H](CC(O)=O)C1 VTIKDEXOEJDMJP-WYUUTHIRSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
239000013566 allergen Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000003510 anti-fibrotic effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000003409 anti-rejection Effects 0.000 description 1
229940124347 antiarthritic drug Drugs 0.000 description 1
238000012458 antifungal assay Methods 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
LKXGYGYFPTZHLC-UHFFFAOYSA-N bicyclo[2.2.1]heptane-4-carboxylic acid Chemical compound C1CC2CCC1(C(=O)O)C2 LKXGYGYFPTZHLC-UHFFFAOYSA-N 0.000 description 1
GINJFDRNADDBIN-FXQIFTODSA-N bilanafos Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCP(C)(O)=O GINJFDRNADDBIN-FXQIFTODSA-N 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
239000011942 biocatalyst Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000004641 brain development Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
208000032343 candida glabrata infection Diseases 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000013000 chemical inhibitor Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
XJHXLMVKYIVZTE-LOALFDMRSA-N chloroeremomycin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(N)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 XJHXLMVKYIVZTE-LOALFDMRSA-N 0.000 description 1
108700008408 chloroeremomycin Proteins 0.000 description 1
101150113676 chr1 gene Proteins 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
229940126142 compound 16 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
108091007930 cytoplasmic receptors Proteins 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000020335 dealkylation Effects 0.000 description 1
238000006900 dealkylation reaction Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
125000004989 dicarbonyl group Chemical group 0.000 description 1
238000002050 diffraction method Methods 0.000 description 1
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
239000000539 dimer Substances 0.000 description 1
AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000012581 double quantum filtered COSY Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
OSERMIPXNLXAPD-MJMYBOKFSA-N elaiophylin Chemical compound O([C@@H]1C[C@@](O)(O[C@H](C)[C@H]1CC)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1[C@H](/C=C/C=C/C(=O)O[C@@H]([C@@H](C)/C=C/C=C/C(=O)O1)[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C)[C@@H](CC)[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)C1)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 OSERMIPXNLXAPD-MJMYBOKFSA-N 0.000 description 1
229950007432 endomycin Drugs 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 1
ZXYAWONOWHSQRU-UHFFFAOYSA-N ethyl 4-oxocyclohexanecarboxylate Chemical compound CCOC(=O)C1CCC(=O)CC1 ZXYAWONOWHSQRU-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
102000033737 extracellular matrix binding proteins Human genes 0.000 description 1
108091009712 extracellular matrix binding proteins Proteins 0.000 description 1
201000007514 familial adenomatous polyposis 1 Diseases 0.000 description 1
101150052705 fap1 gene Proteins 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
244000053095 fungal pathogen Species 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
IUQPDUPFFGXZFJ-UHFFFAOYSA-N glebomycin Chemical compound NC(=N)NC1C(O)C(O)C(O)C(OC(N)=O)C1O.O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1O IUQPDUPFFGXZFJ-UHFFFAOYSA-N 0.000 description 1
102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
150000002373 hemiacetals Chemical class 0.000 description 1
210000004024 hepatic stellate cell Anatomy 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
125000001841 imino group Chemical group [H]N=* 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940124622 immune-modulator drug Drugs 0.000 description 1
230000007365 immunoregulation Effects 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000031261 interleukin-10 production Effects 0.000 description 1
230000022023 interleukin-5 production Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
238000010829 isocratic elution Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000003902 lesion Effects 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
108010088495 lysine cyclodeaminase Proteins 0.000 description 1
229940124302 mTOR inhibitor Drugs 0.000 description 1
150000002678 macrocyclic compounds Chemical class 0.000 description 1
150000007931 macrolactones Chemical group 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
IVSRABABAXUFHF-UHFFFAOYSA-N methoxycyclohexane Chemical compound COC1C=C[CH]C=C1 IVSRABABAXUFHF-UHFFFAOYSA-N 0.000 description 1
BWGIKEUGPCOETD-UHFFFAOYSA-N methyl bicyclo[2.2.1]heptane-3-carboxylate Chemical compound C1CC2C(C(=O)OC)CC1C2 BWGIKEUGPCOETD-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
229960004866 mycophenolate mofetil Drugs 0.000 description 1
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
VSPPONOIKZXUBJ-UHFFFAOYSA-N n,n-diethylethanamine;oxolane Chemical compound C1CCOC1.CCN(CC)CC VSPPONOIKZXUBJ-UHFFFAOYSA-N 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000000508 neurotrophic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
XGECDDPXIKFBTE-AUFVQPSPSA-N ossamycin Chemical compound O1[C@@H](C[C@H](O)CC)CCC[C@]11O[C@H]([C@H]2C)C[C@]3(O)OC(C)(C)C[C@H]3/C=C/CCCCC[C@@](C)(O)[C@H](O)[C@@H](O[C@@H]3O[C@@H](C)[C@H](CC3)N(C)C)[C@H](O)[C@@H](C)[C@H](O)[C@](C)(O)/C=C/C(=O)O[C@H]2C1 XGECDDPXIKFBTE-AUFVQPSPSA-N 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 1
230000010287 polarization Effects 0.000 description 1
108010093101 pristinamycin IIA synthase Proteins 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
150000003147 proline derivatives Chemical class 0.000 description 1
150000003148 prolines Chemical class 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
230000004853 protein function Effects 0.000 description 1
CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
238000000746 purification Methods 0.000 description 1
GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
230000021411 regulation of translational initiation Effects 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000250 revascularization Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
108010092841 ribosomal protein S12 Proteins 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
102220101549 rs199890548 Human genes 0.000 description 1
102220012898 rs397516346 Human genes 0.000 description 1
229930000044 secondary metabolite Natural products 0.000 description 1
210000000413 sensory ganglia Anatomy 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000009131 signaling function Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
101150007336 sre gene Proteins 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000003956 synaptic plasticity Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
108010029517 tacrolimus binding protein 1B Proteins 0.000 description 1
230000003390 teratogenic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
SHINASQYHDCLEU-UHFFFAOYSA-N trans-4-aminoproline Natural products NC1CNC(C(O)=O)C1 SHINASQYHDCLEU-UHFFFAOYSA-N 0.000 description 1
KKJQZEWNZXRJFG-UHFFFAOYSA-N trans-4-methylproline Natural products CC1CNC(C(O)=O)C1 KKJQZEWNZXRJFG-UHFFFAOYSA-N 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
108010050327 trypticase-soy broth Proteins 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1